You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明生物(02269.HK)附屬收購Bayer位於德國的製造工廠的設施資產
格隆匯 01-16 08:40

格隆匯1月16日丨藥明生物(02269.HK)公佈,公司間接全資附屬公司WuXi Biologics Germany與Bayer於1月16日訂立資產購買協議,據此,WuXi Biologics Germany將向Bayer購買位於德國利華古遜的生物藥製劑cGMP灌裝製造工廠的設施資產,以持續擴大集團的產能,進一步滿足全球對生物藥生產不斷增長的需求。

公告顯示,為確保收購後製造工廠營運順暢,WuXi Biologics Germany亦與Bayer分別就製造工廠房屋的長期分租及若干相關過渡服務訂立分租協議及過渡服務協議。

據悉,同資產購買協議,WuXi Biologics Germany自Bayer處分租用於製造工廠的D201大樓的區域及相關儲存及管理區域,整體樓面總面積約為8,768平方米。

公司表示,集團將獲得優質生物藥製劑生產能力,以繼續支持其最近於中國及海外的強勁增長。交易符合公司整體發展計劃,進一步擴大集團製造能力及使其更多元化,併為其全球合作伙伴提供優質的供應鏈網絡,以通過其"藥明生物提供全球雙廠生產"策略惠及全球病患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account